vs

Side-by-side financial comparison of Axogen, Inc. (AXGN) and CapsoVision, Inc (CV). Click either name above to swap in a different company.

Axogen, Inc. is the larger business by last-quarter revenue ($59.9M vs $3.5M, roughly 16.9× CapsoVision, Inc). Axogen, Inc. runs the higher net margin — -22.0% vs -223.9%, a 201.9% gap on every dollar of revenue. Axogen, Inc. produced more free cash flow last quarter ($1.8M vs $-5.7M).

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...

CapsoVision, Inc. is a medical technology firm specializing in the development and manufacturing of advanced capsule endoscopy systems and supporting diagnostic solutions. Its non-invasive gastrointestinal imaging products are supplied to hospitals, gastroenterology clinics and medical specialists across global markets, supporting more accurate detection of digestive diseases and improved patient care experiences.

AXGN vs CV — Head-to-Head

Bigger by revenue
AXGN
AXGN
16.9× larger
AXGN
$59.9M
$3.5M
CV
Higher net margin
AXGN
AXGN
201.9% more per $
AXGN
-22.0%
-223.9%
CV
More free cash flow
AXGN
AXGN
$7.5M more FCF
AXGN
$1.8M
$-5.7M
CV

Income Statement — Q4 2025 vs Q3 2025

Metric
AXGN
AXGN
CV
CV
Revenue
$59.9M
$3.5M
Net Profit
$-13.2M
$-7.9M
Gross Margin
74.1%
54.1%
Operating Margin
-16.3%
-226.7%
Net Margin
-22.0%
-223.9%
Revenue YoY
21.3%
Net Profit YoY
-3023.6%
EPS (diluted)
$-0.28
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXGN
AXGN
CV
CV
Q4 25
$59.9M
Q3 25
$60.1M
$3.5M
Q2 25
$56.7M
$3.3M
Q1 25
$48.6M
Q4 24
$49.4M
Q3 24
$48.6M
Q2 24
$47.9M
Q1 24
$41.4M
Net Profit
AXGN
AXGN
CV
CV
Q4 25
$-13.2M
Q3 25
$708.0K
$-7.9M
Q2 25
$579.0K
$-4.6M
Q1 25
$-3.8M
Q4 24
$450.0K
Q3 24
$-1.9M
Q2 24
$-1.9M
Q1 24
$-6.6M
Gross Margin
AXGN
AXGN
CV
CV
Q4 25
74.1%
Q3 25
76.6%
54.1%
Q2 25
74.2%
54.6%
Q1 25
71.9%
Q4 24
76.1%
Q3 24
74.9%
Q2 24
73.8%
Q1 24
78.8%
Operating Margin
AXGN
AXGN
CV
CV
Q4 25
-16.3%
Q3 25
3.2%
-226.7%
Q2 25
3.0%
-140.3%
Q1 25
-3.4%
Q4 24
4.1%
Q3 24
-0.6%
Q2 24
-0.9%
Q1 24
-11.0%
Net Margin
AXGN
AXGN
CV
CV
Q4 25
-22.0%
Q3 25
1.2%
-223.9%
Q2 25
1.0%
-139.5%
Q1 25
-7.9%
Q4 24
0.9%
Q3 24
-3.8%
Q2 24
-4.0%
Q1 24
-16.0%
EPS (diluted)
AXGN
AXGN
CV
CV
Q4 25
$-0.28
Q3 25
$0.01
$-0.17
Q2 25
$0.01
$-2.02
Q1 25
$-0.08
Q4 24
$-0.00
Q3 24
$-0.04
Q2 24
$-0.04
Q1 24
$-0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXGN
AXGN
CV
CV
Cash + ST InvestmentsLiquidity on hand
$41.5M
Total DebtLower is stronger
$48.4M
Stockholders' EquityBook value
$128.8M
$20.4M
Total Assets
$221.7M
$25.7M
Debt / EquityLower = less leverage
0.38×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXGN
AXGN
CV
CV
Q4 25
$41.5M
Q3 25
$35.8M
Q2 25
$29.9M
Q1 25
$22.1M
Q4 24
$33.5M
Q3 24
$24.5M
Q2 24
$21.1M
Q1 24
$17.6M
Total Debt
AXGN
AXGN
CV
CV
Q4 25
$48.4M
Q3 25
$48.2M
Q2 25
$47.9M
Q1 25
$47.7M
Q4 24
$47.5M
Q3 24
$47.3M
Q2 24
$47.0M
Q1 24
$46.8M
Stockholders' Equity
AXGN
AXGN
CV
CV
Q4 25
$128.8M
Q3 25
$120.8M
$20.4M
Q2 25
$112.3M
$-139.0M
Q1 25
$105.4M
Q4 24
$103.9M
Q3 24
$99.4M
Q2 24
$95.7M
Q1 24
$93.2M
Total Assets
AXGN
AXGN
CV
CV
Q4 25
$221.7M
Q3 25
$216.4M
$25.7M
Q2 25
$205.5M
$9.5M
Q1 25
$196.2M
Q4 24
$203.7M
Q3 24
$192.0M
Q2 24
$188.9M
Q1 24
$186.5M
Debt / Equity
AXGN
AXGN
CV
CV
Q4 25
0.38×
Q3 25
0.40×
Q2 25
0.43×
Q1 25
0.45×
Q4 24
0.46×
Q3 24
0.48×
Q2 24
0.49×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXGN
AXGN
CV
CV
Operating Cash FlowLast quarter
$3.0M
$-5.7M
Free Cash FlowOCF − Capex
$1.8M
$-5.7M
FCF MarginFCF / Revenue
3.0%
-160.5%
Capex IntensityCapex / Revenue
2.1%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-2.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXGN
AXGN
CV
CV
Q4 25
$3.0M
Q3 25
$3.2M
$-5.7M
Q2 25
$7.7M
$-9.5M
Q1 25
$-13.2M
Q4 24
$8.7M
Q3 24
$3.9M
Q2 24
$4.2M
Q1 24
$-12.3M
Free Cash Flow
AXGN
AXGN
CV
CV
Q4 25
$1.8M
Q3 25
$1.7M
$-5.7M
Q2 25
$7.0M
$-9.6M
Q1 25
$-13.4M
Q4 24
$8.1M
Q3 24
$3.3M
Q2 24
$3.3M
Q1 24
$-13.2M
FCF Margin
AXGN
AXGN
CV
CV
Q4 25
3.0%
Q3 25
2.8%
-160.5%
Q2 25
12.4%
-289.0%
Q1 25
-27.7%
Q4 24
16.3%
Q3 24
6.8%
Q2 24
6.8%
Q1 24
-31.9%
Capex Intensity
AXGN
AXGN
CV
CV
Q4 25
2.1%
Q3 25
2.5%
0.3%
Q2 25
1.3%
2.1%
Q1 25
0.5%
Q4 24
1.4%
Q3 24
1.2%
Q2 24
1.9%
Q1 24
2.2%
Cash Conversion
AXGN
AXGN
CV
CV
Q4 25
Q3 25
4.55×
Q2 25
13.35×
Q1 25
Q4 24
19.41×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons